Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS) said management will participate in the Bank of America Securities 2026 Health Care Conference in Las Vegas on May 12, 2026 at 9:20am PT in a fireside chat.

A live webcast will be available via the company’s Investor Relations "News & Events" page.

News Market Reaction – MLYS

-1.25%

2 alerts

-1.25% Session close to close

$2.41B Market Cap

1.55K Volume

In the May 5 session, MLYS declined 1.25%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Mineralys’ participation in a major health care conference, potentially...

Analysis

This announcement highlights Mineralys’ participation in a major health care conference, potentially increasing visibility around its hypertension-focused pipeline. In recent months, the company reported FDA acceptance of its lorundrostat NDA with a PDUFA date of Dec 22, 2026 and year-end cash and investments of $656.6 million. Investors may watch for any new disclosures from the fireside chat, future regulatory milestones, and how these align with prior clinical data and recent insider trading activity marked as Net Selling.

Key Figures

Conference dates: May 11–14, 2026 Presentation date: May 12, 2026 Presentation time: 9:20 a.m. PT

3 metrics

Conference dates May 11–14, 2026 Bank of America Securities Health Care Conference

Presentation date May 12, 2026 Scheduled conference fireside chat

Presentation time 9:20 a.m. PT Fireside chat session at conference

Historical Context

5 past events · Latest: Apr 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	Earnings call scheduling	Positive	+4.3%	Set date and time for Q1 2026 results call and webcast.
Mar 24	Executive appointment	Positive	-3.3%	Appointed Jeffrey A. Munsie as Chief Legal Officer with equity awards.
Mar 16	Inducement equity awards	Positive	-2.8%	Reported stock option and RSU inducement grants to a new employee.
Mar 12	Earnings and update	Positive	-3.0%	Reported Q4 2025 results, NDA acceptance, cash position, and trial updates.
Mar 09	Regulatory and clinical	Positive	+4.4%	Announced FDA NDA acceptance for lorundrostat and topline Explore-OSA data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across recent news, positive operational updates have sometimes aligned with price gains, but there are more instances where seemingly favorable or neutral announcements coincided with short-term pullbacks.

Recent Company History

Over the last six months, Mineralys has reported several corporate and regulatory milestones. On Mar 9, 2026, the company announced FDA acceptance of the NDA for lorundrostat with a PDUFA date of Dec 22, 2026, which coincided with a 4.37% gain. A Q4 2025 update on Mar 12, 2026 highlighted cash and investments of $656.6 million and multiple positive pivotal trials but was followed by a -2.96% move. Subsequent inducement award and leadership announcements saw mixed reactions. The latest pre-announcement of Q1 2026 results on Apr 29, 2026 was followed by a 4.26% increase, showing event-driven volatility around corporate communications.

Key Terms

chronic kidney disease (ckd), obstructive sleep apnea (osa), aldosterone

3 terms

chronic kidney disease (ckd) medical

"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"

Chronic kidney disease (CKD) is a long-term decline in the kidneys’ ability to filter waste and balance fluids and chemicals in the body, often progressing slowly over months or years; think of it as a filter that gradually becomes clogged and less effective. It matters to investors because CKD drives demand for drugs, dialysis, transplants, diagnostics and related medical devices, influences healthcare costs and reimbursement decisions, and is a common target for clinical trials and regulatory review.

obstructive sleep apnea (osa) medical

"chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"

A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.

aldosterone medical

"other diseases driven by dysregulated aldosterone, announced that management"

Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced that management will be participating in the Bank of America Securities 2026 Health Care Conference being held in Las Vegas on May 11-14, 2026.

Bank of America Securities Health Care Conference
Date:	Tuesday, May 12, 2026
Time:	9:20am PT
Format:	Fireside Chat
Webcast Link

A live webcast of this fireside chat can also be accessed on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Melyssa Weible
Elixir Health Public Relations
Email: mweible@elixirhealthpr.com

FAQ

When will Mineralys Therapeutics (MLYS) present at the Bank of America Health Care Conference in May 2026?

Mineralys will present on Tuesday, May 12, 2026 at 9:20am PT in a fireside chat. According to Mineralys Therapeutics, the session is part of the Bank of America Securities 2026 Health Care Conference in Las Vegas and is open via webcast.

How can investors watch the Mineralys Therapeutics (MLYS) fireside chat on May 12, 2026?

Investors can access a live webcast on the company’s Investor Relations "News & Events" page. According to Mineralys Therapeutics, the webcast will stream the fireside chat during the Bank of America Securities 2026 Health Care Conference.

What format will Mineralys Therapeutics (MLYS) use for its Bank of America conference presentation?

The company will present in a fireside chat format at the conference. According to Mineralys Therapeutics, this conversational format is scheduled for May 12, 2026 at 9:20am PT and will be available via webcast.

Will Mineralys Therapeutics (MLYS) provide a replay of the May 12, 2026 conference session?

A live webcast will be available, and a replay is typically posted on the Investor Relations site after the event. According to Mineralys Therapeutics, attendees can check the "News & Events" page for access and any on-demand recording.

What topics might Mineralys Therapeutics (MLYS) discuss at the May 12, 2026 Bank of America conference?

The company is expected to discuss its programs targeting hypertension, CKD, and related comorbidities. According to Mineralys Therapeutics, management will cover clinical and corporate updates during the fireside chat at the May 12, 2026 session.